Mark Sellin
Overview
Explore the profile of Mark Sellin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
12
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sellin M, Berg S, Hagen P, Zhang J
Transl Oncol
. 2022 Jun;
22:101448.
PMID: 35660848
Multiple myeloma (MM) treatment regimens have vastly improved since the introduction of immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies; however, MM is considered an incurable disease due to inevitable relapse...
2.
Hagen P, Sellin M, Berg S, Zhang J
Ann Hematol
. 2022 May;
101(7):1407-1420.
PMID: 35585246
Our understanding of MM genomics has expanded rapidly in the past 5-10 years as a consequence of cytogenetic analyses obtained in routine clinical practice as well as the ability to...
3.
Zhang L, Luo H, Ni H, Liu S, Xing H, Zhang J, et al.
Stem Cell Reports
. 2022 May;
17(6):1428-1441.
PMID: 35561683
Receptor-interacting protein kinase 3 (Ripk3) is one of the critical mediators of inflammatory cytokine-stimulated signaling. Here we show that Ripk3 signaling selectively regulates both the number and the function of...
4.
Sellin M, Mack R, Rhodes M, Zhang L, Berg S, Joshi K, et al.
Br J Cancer
. 2022 Apr;
127(2):223-236.
PMID: 35422078
Introduction: Splice modulators have been assessed clinically in treating haematologic malignancies exhibiting splice factor mutations and acute myeloid leukaemia. However, the mechanisms by which such modulators repress leukaemia remain to...